Oppenheimer Asset Management Inc. Supernus Pharmaceuticals, Inc. Transaction History

Oppenheimer Asset Management Inc.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2020 Aug 11, 2020	SELL	$17.09 - $24.89 $324 - $472	-19 Closed	0 $0
Q1 2020 May 08, 2020	SELL	$14.45 - $24.69 $751 - $1,283	-52 Reduced 73.24%	19 $0
Q3 2019 Oct 31, 2019	SELL	$25.47 - $33.37 $262,239 - $343,577	-10,296 Reduced 99.32%	71 $2,000
Q2 2019 Aug 09, 2019	SELL	$29.96 - $38.87 $109,863 - $142,536	-3,667 Reduced 26.13%	10,367 $343,000
Q1 2019 Apr 24, 2019	SELL	$32.77 - $41.99 $148,087 - $189,752	-4,519 Reduced 24.36%	14,034 $491,000
Q4 2018 Jan 30, 2019	BUY	$30.84 - $49.51 $115,341 - $185,167	3,740 Added 25.25%	18,553 $616,000
Q3 2018 Oct 26, 2018	BUY	$42.7 - $56.55 $53,417 - $70,744	1,251 Added 9.22%	14,813 $746,000
Q2 2018 Aug 10, 2018	SELL	$44.1 - $59.85 $74,043 - $100,488	-1,679 Reduced 11.02%	13,562 $812,000
Q1 2018 May 09, 2018	BUY	$37.15 - $46.9 $10,476 - $13,225	282 Added 1.89%	15,241 $698,000
Q3 2017 Nov 14, 2017	BUY	$36.75 - $49.65 $549,743 - $742,714	14,959	14,959 $598,000

285

60.5M

27.7K

11.3K

Ticker SUPN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 53,495,300
Market Cap $2.09B
Description
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...

Get notified when there are updates to the investment portfolio of Oppenheimer Asset Management Inc., based on Form 13F filings with the SEC.

Stay updated on Oppenheimer Asset Management Inc. with notifications on news.